<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341779</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00007544</org_study_id>
    <secondary_id>R01AI147752</secondary_id>
    <nct_id>NCT04341779</nct_id>
  </id_info>
  <brief_title>Simplifying Treatment and Monitoring for HIV</brief_title>
  <official_title>Simplifying Treatment and Monitoring for HIV (STREAM HIV): Point-of-Care Urine Tenofovir Adherence and Viral Load Testing to Improve HIV Outcomes in South Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to determine the clinical efficacy and cost effectiveness of implementing an
      integrated model for HIV monitoring using point of care (POC) tenofovir (TFV) adherence
      testing and POC viral load (VL) monitoring in improving ART adherence, maintaining durable VL
      suppression, and improving retention in care among HIV-positive individuals initiating
      first-line tenofovir disoproxil fumarate (TDF)-based ART in South Africa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a two-arm, open-label, randomized controlled superiority trial at an HIV
      clinic in Durban. HIV-positive individuals aged 16 years and above, who are initiating a
      tenofovir-based, first-line ART will be randomized to receive POC VL testing and POC TFV
      adherence testing, versus standard-of-care (SoC) viral load testing. VL testing will follow
      South African guidelines for HIV VL testing after ART initiation. 540 participants will be
      randomized (1:1) at ART initiation into routine POC TFV adherence testing with POC VL
      monitoring or standard-of-care (SoC) with no objective TFV adherence testing and SoC VL
      monitoring.

      Participants will be followed to compare concentrations between study arms at 24 weeks after
      ART initiation and a composite outcome of VL suppression and retention in care between the
      study arms at 72 weeks after ART initiation. The study will use process evaluation data,
      interviews and focus groups with patients and staff to assess implementation of the POC
      assays. Micro-costing will be conducted to estimate intervention costs.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean tenofovir concentration levels</measure>
    <time_frame>24 weeks after ART initiation</time_frame>
    <description>Tenofovir diphosphate concentrations in blood after ART initiation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite measure of virological suppression and retention in care</measure>
    <time_frame>72 weeks after ART initiation</time_frame>
    <description>HIV VL less than 200 copies/mL by a lab-based reference assay at the study exit</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">540</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Point-of-care adherence testing and Point-of-care viral load testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-of-care arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No adherence and lab-based viral load testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Point-of-care viral load and tenofovir adherence testing</intervention_name>
    <description>Point-of-care testing of HIV viral load and tenofovir and providing same day results to participants</description>
    <arm_group_label>Intervention arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-positive

          -  â‰¥16 years old

          -  Initiating a tenofovir-based, first-line ART regimen

          -  Do not self-report being on an ART regimen in the prior month

          -  Willing/able to provide written informed consent

        Exclusion Criteria:

          -  Does not plan to continue receiving HIV care at the CDC Clinic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Drain, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nigel Garett, MBBS, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fathima Sayed</last_name>
    <phone>+27316550611</phone>
    <email>fathima.sayed@caprisa.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Justice Quame-Amaglo</last_name>
    <phone>2065203866</phone>
    <email>quamaglo@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Fathima Sayed</last_name>
      <phone>+27312604374</phone>
      <email>fathima.sayed@caprisa.org</email>
    </contact>
    <contact_backup>
      <last_name>Nigel Garrett, MBBS, PhD</last_name>
      <phone>+27312604453</phone>
      <email>nigel.garrett@caprisa.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nigel Garrett, MBBS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Paul Drain</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Point-of-care test</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>Adherence</keyword>
  <keyword>HIV viral load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data from the study will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following publication of primary results.</ipd_time_frame>
    <ipd_access_criteria>De-identified generated under this project will be administered in accordance with University of Washington, CAPRISA, and NIH policies, including the NIH Data Sharing Policy and Implementation Guidance of March 5, 2003.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

